EMBARK Psychedelic Therapy for Depression

EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person represents a critical step forward in the field of psychedelic therapy. The book is a comprehensive guide for clinicians, offering a groundbreaking therapeutic framework for administering psychedelic medicines in treating depression. The approach is gaining traction with 4,000 people registered for the EMBARK foundational training. Developed in response to identified gaps inexisting models of psychedelic therapy, the EMBARK model addresses the need for an ethical and inclusive approach. It bridges gaps from previous psychedelic therapies, such as lack of attentiveness to the body andrigorous ethical practice. The EMBARK approach has a growing evidence-base: in a recent psychedelic clinical trial, 79% of participants achieved full remission from depression three weeks after treatment. Benefits persisted with 75% of particpants in remission at the four-month follow up. EMBARK offers a transdiagnostic and trans-drug approach adaptable to various indications and psychedelic medicines. It's built on four Cornerstones of Care: Trauma-Informed Care,Culturally Competent Care, Ethically Rigorous Care, and Collective Care, reflecting the belief that efficacious treatment is ethical treatment. The EMBARK acronym represents six Clinical Domains that commonlyemerge for people in psychedelic experiences: Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum. The book provides practical instructions and suggested agendas for therapists, and offers a flexible, participant-centric approach to integration, focusing on the clinical domains that emerged for the participant. It also links theory to practice for the treatment of depression, drawing from twelve proposedpsychological mechanisms of therapeutic change in psychedelic therapy, and provides a comprehensive guide to treatment factors. EMBARK psychedelic therapy is open-sourced to the clinical community for development andadaptation to other psychedelic medicines, diverse populations, and to inform the development of psychedelic practitioner trainings, making it an essential resource for those interested in the field of psychedelic therapy.

This book marks an exciting milestone in psychedelic-assisted therapy. Not only is it a really comprehensive guide to what to actually 'do,' the authors offer their wisdom from their whole selves, bringing a level of sensitivity and depth that befits these sacred ways of healing. Rosalind Watts, PhD, Founder ACER Integration
There are few people I admire more in this field than Alex Belser. He commits to a meticulous inquiry, infused with integrity. He and Bill Brennan have written a much-needed practical, thoughtful guide to treating the whole being (physical, psychological, spiritual and otherwise) of a depressed person with psychedelic-assisted psychotherapy. Julie Holland, MD, author of Good Chemistry: The Science of Connection, From Soul to Psychedelics (2020)
This comprehensive book reminds us of the depth, range, and complexity of psychedelic experiences, and gives therapists a framework for engaging with the full potential of psychedelic-assisted therapy. It comes at a critical time if we are to remain open to transforming the way we support each other in healing. Michael Mithoefer, MD, MDMA-assisted Therapy Researcher
Well-trained therapists are the key to generating successful outcomes from psychedelic-assisted therapy, the psychedelics themselves are just tools that need to be used wisely and compassionately. Pioneering, comprehensive, and deeply insightful-EMBARK points the way to the future of psychedelic-assisted therapy. Brennan and Belser's commitment to holistic and ethical care is a profoundly valuable guide to practitioners and patients. Rick Doblin, PhD, Founder and President of the Multidisciplinary Association for Psychedelic Studies
Brennan and Belser's remarkable manual offers an approach both visionary and practical. Their method recognizes the psychological, social, and spiritual aspects that are central to the psychedelic healing of depression, allowing the reader to discover the unique location for that therapist, that patient, and the medicine that connects them. Jeffrey Guss, MD, Lead Trainer, Fluence; Clinical Assistant Professor of Psychiatry, NYU Grossman School of Medicine
This book is not only the newest but focused specifically on therapists and the therapist's role in helping clients who are receiving psychedelic-assisted therapy for the treatment of depression. Timothy J. Legg, Doody

Bill Brennan, PhD, is a psychologist in New York City who has served as a clinical advisor at Cybin, Inc. and Gilgamesh Pharmaceuticals. He is a co-creator of the EMBARK approach to psychedelic therapy and is a core faculty member in the EMBARK psychedelic facilitator training program. He has trained and supervised psychedelic facilitators in several studies and has been the lead author of several psychedelic treatment manuals. He currently servesas an advisory board member of New Yorkers for Mental Health Alternatives.Alex Belser, PhD, is a clinical scientist, psychologist, author, and leader in psychedelic research. As a Co-Investigator at Yale University, he is exploring psilocybin therapy to treat OCD. With a strong commitment to developing psychedelic therapies, he has conducted clinical trials investigating the potential of psilocybin, MDMA, ketamine, and DMT in addressing depression, anxiety, addiction, and PTSD. He co-founded the non-profit Nautilus Sanctuary and the New YorkUniversity Psychedelic Research Group in 2006. He served as the Chief Clinical Officer at Cybin and Adelia Therapeutics. He is the co-editor of Queering Psychedelics: From Oppression to Liberation in Psychedelic Medicine(2022).

This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.